Clinuvel Showcases AI Vitiligo Tool and EPP Therapy at Major U.S. Dermatology Meeting

An announcement from Clinuvel Pharmaceuticals ( (AU:CUV) ) is now available.

Clinuvel Pharmaceuticals is showcasing its melanocortin-based programs at the 2026 American Academy of Dermatology Meeting in Denver, highlighting SCENESSE for erythropoietic protoporphyria and its development work in vitiligo. The company is positioning itself as a leader in photomedicine by combining approved therapies with novel tools and strong engagement with dermatology experts.

A key focus is the unveiling of its in-house Vitiligo Visual Algorithm, an AI-driven tool designed to standardise and objectively assess pigmentation changes in vitiligo patients using clinical images. Clinuvel is integrating this technology into current and upcoming vitiligo trials and using its reimagined Pavilion of Photomedicine and sponsored satellite symposia to gather real-time feedback, refine its clinical strategy and deepen relationships within a 20,000-strong dermatology community.

The most recent analyst rating on (AU:CUV) stock is a Hold with a A$10.50 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.

More about Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic and life-threatening acute disorders, as well as healthcare solutions for specialised populations. As a pioneer in photomedicine and melanocortin peptides, its lead therapy SCENESSE is approved in multiple regions as the first systemic photoprotective drug for adults with erythropoietic protoporphyria.

Average Trading Volume: 104,617

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$494.5M

See more insights into CUV stock on TipRanks’ Stock Analysis page.